Major Depression
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
16 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 25 trials with date data
Clinical Trials (26)
Total enrollment: 4,519 patients across 26 trials
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
Inflammatory Markers and Cognitive Function in Major Depression
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache
Use of Risperidone in ECT for Treatment Resistant Depression
Physiologic Monitoring of Antidepressant Response
Functional Neuroimaging in Depression
Pilot BA Study of New LY03005 vs Pristiq
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression
Impact of Capacity Building of Healthcare Workers on Management of Post-Traumatic Stress Disorder
Interpersonal Psychotherapy for Adolescents and Young Adults
Neuroimaging Sleep and Mood in Depression
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health
Depression Management Project
Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living
Adapting Cognitive Behavioral Therapy (CBT) for Chinese Americans
Mineralocorticoid Receptor in the Treatment of Severe Depression
Brain Abnormalities in Late-Onset Major Depression
Chronos: the Use of Chronobiological Treatment in Depression
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
Improving Depression Care for Elders: Coordinating Center
Related Jobs in Neurology
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Behavioral Health Technician (Greenbrook)
Specialist, Quality Assurance
Regional Business Director, Symbravo (Southeast Region)
Regional Business Director, Symbravo (Southwest Region)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.